U.S. Markets closed

AC Immune SA (ACIU)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
7.28+0.17 (+2.39%)
At close: 4:00PM EDT
Sign in to post a message.
  • M
    Mashkoor
    will be $15
    Bullish
  • S
    SONG
    I have thought ACIU is the best pick in Alzheimer's sector boom.
    Until now, this is far behind others but I have used this buying chance.
    With such a robust pipeline, We will see the spectacular result soon...
  • C
    Curtis
    How will this help ACIU since they work with LLY?
    Eli Lilly & Co. said it has received breakthrough therapy designation for its Alzheimer's treatment from the U.S. Food and Drug Administration.

    The designation means preliminary clinical evidence indicates the drug could show substantial improvement over available therapies on a clinically significant endpoint, and is meant to expedite the development and review of drugs for serious conditions, according to the FDA.

    Lilly on Thursday said it plans to submit a biologics license application for the drug, donanemab, under the accelerated approval path later this year based on data from its Phase 2 trial. It said the safety, tolerability and efficacy of donanemab are being evaluated in an ongoing Phase 3 study.
  • M
    Moral empirical
    No more upcoming presentations listed on co website so looks like we’re at the mercy of algos retracing back from $8.64.
    Fibs .23-$8.01
    .38-$7.60
    .5- $7.27
    .62-$6.94
    Jansen will presumably wait for data from additional patients added to the second highest dose cohort of ACI 35.030 before funding decision for ph 3 which they are contractually fully responsible for.
    In Dr. Andrea Pfeifer’s words during June 2 Jeffries interview
    “I’m sure Jansen will come forward very soon with plans on how to develop this molecule “
    Her comment “Soon “, is relative but with Eli Lilly ‘s Donanemab receiving break through status and filing for accelerated later this year who knows what the
    FDA ‘s recent pivot to AD prevention and growing calls for an operation warp speed approach to AD could factor into AD clinical trials.
    Also her comment
    “Jansen has never seen higher more specific antibody titis and they are of the opinion it’s maxed out the immune system” will be another thing to keep an eye on.
    By the way CEO totally skipped over discussing Semorinemab’s final readout scheduled for Q3 even though it was listed right their on the slide of upcoming milestones.
  • J
    Jim
    Does anybody have a more recent statement on when LAURIET is going to be reported versus "the first half of the year" that was reported nine months ago?
  • M
    MrT
    Just following Dievini (billionaire Hopp) $BIIB FDA tearing it down…
    $SAVA run the hype…
    $ACIU insanely undervalued sleeping giant…@ market cap of 0.5, considering the pipeline with 125 people and impressive IP https://www.acimmune.com/en/pipeline-overview/
    Bullish
  • M
    MrT
    Bullish
  • W
    WealthMastersClub1
    $BIIB conversation
    2 largely overlooked biotechs in AD, PD prevention/cure
    BioVie Inc. (BIVI) --- BIVI's NE3107, a selective inhibitor of inflammatory ERK signaling that reduces neuroinflammation. It is an orally administered first-in-class small molecule that inhibits inflammation-driven insulin resistance and major pathological inflammatory cascades with a novel mechanism of action. There is emerging scientific consensus that both inflammation and insulin resistance play fundamental roles in the development of Alzheimer’s and Parkinson’s Disease, and NE3107 could represent an entirely new medical approach to treating these devastating conditions affecting an estimated 6 million Americans suffering from Alzheimer’s and 1 million from Parkinson’s. The FDA recently authorized a pivotal US Phase 3 clinical trial for NE3107.

    AC Immune (ACIU) --- Robust and diverse pipeline of nine therapeutic and three diagnostic product candidates has the potential to greatly improve the treatment of a broad spectrum of Alzheimer’s and neurodegenerative diseases. All of the company’s products were discovered utilizing its proprietary SupraAntigen™ and Morphomer™ technology platforms.
    Partners: Eli Lilly, Janssen (a Johnson&Johnson Co.), Genentech (a Roche Co.), Life Molecular Imaging

    $ACIU $BIVI $SAVA $ANVS $LLY $AVXL
  • B
    Best2Listen
    The Biogen drug is too expensive for the masses. At $50,000 per year and 30M candidates, it will overwhelm medical budgets. This cost will only make the ACIU vaccine more valuable in the fight against Alzheimer's. It might take a while, but this will be a money maker. I'm staying long.
  • G
    GetLucky
    Did I miss something ? Just discovered that a prospectus was issued end of April re. selling upto $80 million worth of common shares via agent Jefferies.
  • S
    SONG
    It is time for Semorinemab and Crenezumab's resurrection.
    Bullish
  • M
    MrT
    Alzheimer cure, can you imagine!! $$$
    currently: $7.5 @ market cap of 0.5; future: Phase 3 soon —> $70 @ market cap 5;
    Launch: $700 @ market cap of 50( only)
    🚀🚀🚀
    Bullish
  • J
    John the Daytripper
    Nice follow-thru today, only down 4%. Finger on the sell button again. It might take 30-40 more "presentations" will get this dog over 8 again.
  • W
    WealthMastersClub1
    ACIU vol rising! Once this sleeper get the attention, it'll spike a lot higher. This company is way undervalued!
    Bullish
  • J
    John the Daytripper
    Wow, what a dive!! Cannot hold 8. Period.
  • C
    Curtis
    I like to start hearing about possibility of a buy out.
  • T
    Thanos-a-diol
    ACIU$ LLY$ Making double digit gains on sympathetic interest based on Aducanumab (BIOGEN) approval. LLY and ACIU still in partnership?
  • J
    John the Daytripper
    Hey Nick, I hear they're going to provide another update in August 2029. Are you holding until then?
  • J
    Jeff
    1.7 million shares traded.
    Bullish